Cytokinetics, Incorporated (NASDAQ:CYTK) Stock Holdings Lifted by Brown Advisory Inc.

Brown Advisory Inc. lifted its holdings in Cytokinetics, Incorporated (NASDAQ:CYTK) by 0.9% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 1,086,300 shares of the biopharmaceutical company’s stock after buying an additional 9,869 shares during the quarter. Brown Advisory Inc. owned approximately 0.91% of Cytokinetics worth $43,658,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of CYTK. Jones Financial Companies Lllp increased its holdings in shares of Cytokinetics by 189.8% in the 4th quarter. Jones Financial Companies Lllp now owns 571 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 374 shares during the period. Fifth Third Bancorp increased its holdings in shares of Cytokinetics by 42.2% in the 1st quarter. Fifth Third Bancorp now owns 981 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 291 shares during the period. Parallel Advisors LLC increased its holdings in shares of Cytokinetics by 500.5% in the 1st quarter. Parallel Advisors LLC now owns 1,099 shares of the biopharmaceutical company’s stock worth $44,000 after acquiring an additional 916 shares during the period. GAMMA Investing LLC increased its holdings in shares of Cytokinetics by 281.0% in the 1st quarter. GAMMA Investing LLC now owns 1,120 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 826 shares during the period. Finally, UMB Bank n.a. increased its holdings in shares of Cytokinetics by 91.4% in the 1st quarter. UMB Bank n.a. now owns 1,156 shares of the biopharmaceutical company’s stock worth $46,000 after acquiring an additional 552 shares during the period.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. JMP Securities reissued a “market outperform” rating and set a $78.00 target price on shares of Cytokinetics in a research note on Thursday, April 10th. Barclays lowered their target price on shares of Cytokinetics from $55.00 to $53.00 and set an “overweight” rating on the stock in a research note on Thursday, May 8th. Royal Bank Of Canada lowered their target price on shares of Cytokinetics from $82.00 to $80.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 7th. Bank of America lowered their target price on shares of Cytokinetics from $62.00 to $54.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 15th. Finally, JPMorgan Chase & Co. lowered their target price on shares of Cytokinetics from $71.00 to $53.00 and set an “overweight” rating on the stock in a research note on Monday, June 9th. Three investment analysts have rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Cytokinetics has a consensus rating of “Moderate Buy” and a consensus target price of $70.92.

Cytokinetics Trading Up 2.7%

NASDAQ:CYTK opened at $34.25 on Wednesday. Cytokinetics, Incorporated has a twelve month low of $29.31 and a twelve month high of $61.38. The company has a 50-day moving average of $32.98 and a 200-day moving average of $40.38. The firm has a market cap of $4.09 billion, a price-to-earnings ratio of -6.47 and a beta of 0.59.

Cytokinetics (NASDAQ:CYTK) last announced its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.36) EPS for the quarter, topping the consensus estimate of ($1.41) by $0.05. The firm had revenue of $1.60 million during the quarter, compared to analyst estimates of $2.77 million. During the same quarter in the previous year, the business earned ($1.33) earnings per share. The business’s quarterly revenue was up 89.1% compared to the same quarter last year. On average, research analysts forecast that Cytokinetics, Incorporated will post -5.24 earnings per share for the current year.

Insider Buying and Selling

In related news, Director John T. Henderson sold 3,190 shares of the firm’s stock in a transaction that occurred on Tuesday, April 15th. The shares were sold at an average price of $38.66, for a total transaction of $123,325.40. Following the completion of the sale, the director directly owned 66,348 shares in the company, valued at approximately $2,565,013.68. This trade represents a 4.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Wendall Wierenga sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $38.46, for a total transaction of $769,200.00. Following the sale, the director owned 24,848 shares of the company’s stock, valued at approximately $955,654.08. This represents a 44.60% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 64,941 shares of company stock valued at $2,334,186. Company insiders own 3.40% of the company’s stock.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.